What is Jyong Biotech Ltd. Ordinary Shares (MENS) stock price today?

Jyong Biotech Ltd. Ordinary Shares (MENS) currently trades at $2.05 per share. The stock has a market capitalization of $163.46M and a P/E ratio of —x.

Is MENS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Jyong Biotech Ltd. Ordinary Shares has a Smart Value Score of 17/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -10.55.

Is Jyong Biotech Ltd. Ordinary Shares financially healthy?

Jyong Biotech Ltd. Ordinary Shares's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -10.55 places it in the distress.

MENS

Jyong Biotech Ltd. Ordinary Shares

NASDAQ: MENS · HEALTHCARE · BIOTECHNOLOGY

$2.05

+0.00% today

Updated 2026-05-08

Market cap

$163.46M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.04

Dividend yield

—

52W range

$1 – $67

Volume

0.2M

Market cap

$163.46M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.04

Dividend yield

—

52W range

$1 – $67

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.5

Quality

3.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-10.6

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →195 stocks currently score above 75

Price targets

Analyst target

$—

—

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

+ Debt/equity -1.57x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -10.55 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-913000.00

Key financials

Revenue Net Income Free Cash Flow

Metric	2021	2022	2023	2024	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	—
Net income	$-4.20M	$-6.63M	$-4.40M	$-3.02M	$-1.25M
EPS	—	—	—	—	$-0.04
Free cash flow	$-2.12M	$-3.22M	$-2.60M	$-3.62M	$-913000.00
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MENS	$163.46M	17	4.3	3.5	5.0	4.5	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-38.45%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-20.52%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+42.20%	Buy
AZN	$286.68B	62	6.0	8.5	5.3	5.0	+6.60%	Buy

Smart narrative

Jyong Biotech Ltd. Ordinary Shares trades at $2.05. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -10.55, it sits in the distress.

Frequently asked questions

What is Jyong Biotech Ltd. Ordinary Shares's stock price?

Jyong Biotech Ltd. Ordinary Shares (MENS) trades at $2.05.

Is Jyong Biotech Ltd. Ordinary Shares overvalued?

Smart Value Score 17/100 (Grade F, Strong Sell).

What is the price target of Jyong Biotech Ltd. Ordinary Shares (MENS)?

The analyst target price is $—, representing NaN% downside from the current price of $2.05.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-10.55 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

jyongbio.com

Quick metrics

P/S ratio—

ROE—

Beta—

50D MA$2.23

200D MA$23.17

Shares out0.07B

Float0.03B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MENS vs LLY →MENS vs JNJ →MENS vs ABBV →Stock screener →